GlassScriptPhysician profile
Mallory Lake
NPI 1699149906
$607.81
in general payments reported to CMS, 2019-2025
21 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.11 · 2022: $36.42 · 2023: $143 · 2024: $281 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $78.09 | 2024 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.77 | 2025 | Caplyta |
| Abbvie INC. | $43.32 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $41.68 | 2023-2024 | Rexulti, Abilify Maintena |
| Bausch Health US, LLC | $38.53 | 2023-2024 | Wellbutrin, Aplenzin |
| Janssen Pharmaceuticals, INC | $37.16 | 2024 | Invega Sustenna, Spravato |
| Abbott Laboratories | $36.78 | 2021-2023 | Freestyle Libre 3 |
| Lundbeck LLC | $29.87 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $28.66 | 2023-2024 | Trintellix |
| Alkermes, INC. | $28.58 | 2024 | Aristada, Lybalvi |
| Novo Nordisk INC | $22.86 | 2022 | |
| Lilly USA, LLC | $21.74 | 2023 | Olumiant, Taltz |
| Brainsway USA INC | $20.82 | 2025 | Deep Tms System |
| Teva Pharmaceuticals USA, INC. | $19.55 | 2025 | Austedo Xr |
| Neos Therapeutics, LP | $18.77 | 2024 | Adzenys Xr-Odt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $18.55 | 2023 | Xelstrym |
| Axsome Therapeutics, INC. | $16.70 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $16.46 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $14.99 | 2024 | Hetlioz, Fanapt |
| Almatica Pharma LLC | $14.37 | 2023 | Loreev Xr |
| Pfizer INC. | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Lake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.